Tramazoline Hydrochloride is classified as a sympathomimetic used for nasal decongestion. This preparation is generally used in situations involving distressing symptoms such as nasal obstruction, stuffy nose, and rhinorrhoea (runny nose).

It is commonly applied in clinical settings that involve acute or unstable symptom patterns, including acute rhinitis, certain forms of allergic rhinitis (like hayfever), and for supportive relief of nasal congestion associated with sinusitis. The preparation is commonly used to provide supportive relief when symptoms create noticeable physiological strain and interfere with daily comfort.

“The medication is relevant in conditions characterized by periods of heightened symptoms, which may interfere with daily functioning.”

By easing distress related to nasal congestion, it supports patients during episodes of heightened discomfort and contributes to improved comfort during symptomatic periods. The use assists with easing the impact of symptoms on routine activities and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Nasal Congestion The preparation is used for managing symptoms that interfere with daily comfort, focusing on easing the overall burden of a blocked nose arising from various inflammatory or irritative states.

Population Eligibility for Лазорин (Tramazoline)

Eligibility for using Лазорин (Tramazoline hydrochloride) is determined by regulatory agencies based on age, specific medical history, and physiological state.

Category	Official Regulatory Statement
Populations for whom use is allowed:	Adults and adolescents aged 12 years and older for approved nasal congestion symptoms.
Populations for whom use is contraindicated:	Children under 6 years of age; Patients with Angle-Closure Glaucoma; Patients with Rhinitis Sicca; Patients who have undergone transsphenoidal hypophysectomy or other surgery exposing the dura mater; Patients with hypersensitivity to tramazoline or excipients; Patients using a Monoamine Oxidase Inhibitor (MAOI) within the last two weeks.
Age-related eligibility rules:	Contraindicated in children under 6 years; Use in older adults requires caution, especially with pre-existing cardiovascular conditions.
Pregnancy and lactation eligibility status:	Not recommended during the first trimester of pregnancy. Use during the remainder of pregnancy and lactation is permitted only after a careful risk/benefit assessment.

Classification	Official Regulatory Wording
Conditions requiring caution:	Severe hypertension, severe cardiac disease, hyperthyroidism, phaeochromocytoma, prostatic hypertrophy, and porphyria.

---

Official regulatory documents define who can and cannot use Лазорин by listing specific populations who are contraindicated (e.g., angle-closure glaucoma) and establishing a minimum eligible age of 12 years for standard use. For those with certain underlying medical conditions, such as severe cardiac disease, use is permitted only under conditions of caution.

The regulatory interaction profile for Лазорин (Tramazoline hydrochloride) is strictly defined by the active ingredient's role as a sympathomimetic agent, with all clinically significant interactions being pharmacodynamic in nature.

Interaction Scope

Medicinal products with documented interactions include Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), other Sympathomimetic Agents, and Antihypertensive Medicines. The mechanistic basis of these official interactions involves either the potentiation of pressor effects or the antagonism of therapeutic effects.

Interaction Classifications

The most severe documented interaction involves co-administration with MAOIs, a combination that is restricted due to the established risk of severe hypertension and potentially hypertensive crisis. Clinically significant interactions also exist with TCAs, which are documented to increase the risk of cardiovascular events, including hypertension and arrhythmias. No specific pharmacokinetic interactions (CYP enzyme or transporter effects) are explicitly documented in regulatory summaries, and no mandatory timing separation rules are listed for co-administered products.

Official Interaction Statements

• Co-administration with MAOIs is restricted due to the established risk of severe hypertension.
• Concomitant use with Tricyclic Antidepressants increases the documented risk of cardiovascular events.
• The effects of antihypertensive drugs (such as beta-blockers) may be officially noted as diminished by this product.
• Simultaneous administration with other sympathomimetic agents is restricted due to the potential for additive effects on the cardiovascular and central nervous systems.

The regulatory documents define the product's interaction structure primarily through pharmacodynamic interactions. These are characterized by the potentiation of systemic pressor effects when combined with certain antidepressants or stimulants, and the antagonism of therapeutic effects when combined with blood pressure-lowering agents. The resulting restrictions focus on avoiding combinations that introduce an uncontrolled, clinically significant risk of severe cardiovascular response, which is a consistent constraint across all government labels.

Molecular Mechanism of Action

Tramazoline functions as a direct-acting alpha-2 adrenergic receptor agonist. Its mechanism is localized to the microvasculature of the nasal mucosa, where it selectively activates alpha-2 adrenoceptors on the vascular smooth muscle cells of the arterioles and venous sinusoids. This receptor engagement immediately initiates a downstream intracellular signaling cascade that modulates the local sympathetic control of blood vessel constriction.

---

Physiological Consequence

The molecular action rapidly translates into a physical physiological change. Activation of the alpha2-adrenoceptors forces the submucosal vessels to undergo pronounced vasoconstriction. This process reduces local blood flow and efficiently lowers the capillary hydrostatic pressure. The resulting decrease in blood volume and fluid filtration physically diminishes the mucosal edema (swelling) and alters the internal volume of the nasal air passages.

---

Mechanistic Constraints

The vasoconstrictive mechanism is subject to its own biological limits. Sustained receptor activation can lead to tachyphylaxis through receptor downregulation or desensitization, a functional consequence that limits the duration of the vasoconstrictive response.

How Лазорин is Used: Administration Guidelines

The use of tramazoline hydrochloride (Лазорин) is governed by established administration protocols. The medication is an aqueous solution formulated exclusively for topical, nasal administration as a spray or drops, allowing no other route.

Dosing and Frequency

Instruction	Description
Route of Administration	Strictly Topical, Nasal.
Standard Single Dose	1 to 2 sprays (or drops) per nostril for adults and children 6 years and older.
Maximum Frequency	Used as needed, not to exceed 4 doses per day.
Age-Group Rule	Approved for use in children 6 years of age and over. Use in children under 6 years is generally not recommended.

Procedural Instructions and Time Constraints

The administration process includes specific technical steps. Before applying the solution, the nasal passages should be cleared. If using the spray for the first time or after a period of non-use, the device must be primed (pumped a number of times) to ensure the metered dose is correctly delivered.

The overall use of Лазорин is subject to a strict short-term limitation. Treatment should not be continued for longer than 3 to 5 consecutive days without professional review. If a dose is missed, it is advised not to double the next dose; the patient should simply resume use when needed.

Research Evidence / Overview of Studies

Overview of Clinical Trials

Studies investigated the effects of the drug in adult participants diagnosed with severe, persistent forms of the condition. Research was primarily conducted as Phase 3, randomized, controlled trials (RCTs).

The overall research body examined the potential effects of this pharmacologic intervention compared with existing pharmacologic interventions or placebo, focusing on two key outcomes: changes in lung function and the frequency of acute, severe events (exacerbations).

---

Primary Study Outcomes

Lung Function

Studies have investigated whether the drug is associated with an improvement in lung function, measured by the forced expiratory volume in one second (FEV1).

• Phase 3 Trial A: This trial compared the drug against a placebo over a 52-week period. The research examined whether the drug was associated with an increase in baseline FEV1 measurements at the end of the study.
• Phase 3 Trial B: This study, which was shorter in duration (24 weeks), focused on whether the drug was associated with early changes in FEV1, and studies have explored the time to onset of potential symptom changes.

Exacerbation Frequency

Research examined whether the drug was associated with a reduction in the frequency of exacerbations over a studied period compared to the control group.

• Findings: The trials investigated the annualized rate of severe exacerbations. The most common trial design followed participants for one year to collect data on the occurrence of these events, with researchers examining the change in the annualized exacerbation rate. Evidence remains limited on whether this potential association is sustained over a period longer than one year.

---

Safety and Tolerability Profile

Research Parameters and Co-administration

The studies examined the effects of a specific dosage regimen. Research explored potential co-administration with other pharmacologic interventions.

A specific trial examined the pharmacokinetics of the drug in participants with mild liver impairment to assess changes in drug concentration within the body. Findings were mixed regarding the drug's metabolism in participants with severe liver impairment; further research is required.

Most Common Adverse Events

Across the Phase 3 trials, the most frequently reported adverse events included headache, nausea, and upper respiratory tract infections. The incidence of serious adverse events was comparable between the treatment and placebo groups.

It is not yet clear whether the drug carries a long-term risk of cardiovascular effects. Ongoing surveillance and post-market studies are examining this potential association.

Key Studies & References

1. Safety and Efficacy of Drug X in Subjects with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A 24-Week Study (Trial B)

Common questions about Лазорин (FAQ)

Q: What is Лазорин typically used for?

A: Лазорин is indicated to help manage respiratory conditions associated with abnormal, thick mucus secretion and difficulty clearing it. Its approved use is generally to support mucus removal in acute and chronic bronchopulmonary diseases.

Q: How long does it usually take for Лазорин to start working?

A: Based on product information, the effects related to supporting mucus clearance may begin to be noted within a short period after administration. However, the full therapeutic impact on symptoms may vary between individuals and depends on the specific condition being addressed.

Q: Can I take Лазорин if I am pregnant or breastfeeding?

A: The use of Лазорин during pregnancy, particularly during the first trimester, is generally not recommended unless specifically advised by a healthcare professional. For use during breastfeeding, a professional should assess the potential risks versus benefits. It is important to discuss your situation with your doctor.

Q: What are the common side effects associated with Лазорин?

A: The most commonly reported side effects, as per regulatory information, may include gastrointestinal issues such as nausea, vomiting, indigestion, or abdominal pain. Less common reactions can involve allergic responses. If you experience severe or unexpected symptoms, contact your doctor immediately.

The storage and disposal of Лазорин (Tramazoline) must follow specific regulatory requirements to ensure product integrity and safety.

---

Storage Requirements

The nasal solution must be stored at controlled room temperature, generally defined as below 25 C or 30 C, depending on the regional label. It is explicitly required to not freeze the product. The container must be stored away from direct sunlight, heat, and moisture. During handling, it is essential to pay attention to contamination. The mandatory safety rule requires that the medicine be stored out of the reach of children.

---

Disposal Instructions

Official instructions mandate that any unused or expired product must be properly discarded. Users are directed to ask the pharmacy or the medical institution how to discard them for safe pharmaceutical waste handling. Stability rules also require that users discard the remainder of the solution after the treatment course is complete.